Latest News and Press Releases

HAWTHORNE, N.Y., Oct. 13, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. ("Taro") (Nasdaq:TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. ("Taro USA"), its U.S. affiliate, has...

HAWTHORNE, N.Y., Aug. 20, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) ("Taro") reported today that it has received approval from the U.S. Food and Drug Administration...

HAWTHORNE, N.Y., July 29, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that its U.S. affiliate has received final approval from the U.S. Food and Drug...

HAWTHORNE, N.Y., July 27, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) intends to report financial results for the second quarter of 2004 prior to the Nasdaq market opening...

HAWTHORNE, N.Y., June 1, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration...

HAWTHORNE, N.Y., Feb. 13, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) intends to report financial results for the fourth quarter and full year 2003 prior to the Nasdaq...

HAWTHORNE, N.Y., Jan. 8, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) today announced that its U.S. affiliate has expanded its distribution capacity with the purchase of a...

HAWTHORNE, N.Y., Dec. 01, 2003 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) today announced the completion of a $50 million offering of long-term, non-convertible debt to...

HAWTHORNE, N.Y., Nov. 17, 2003 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that its U.S. affiliate has filed an Abbreviated New Drug Application ("ANDA") with the...

HAWTHORNE, N.Y., Nov. 14, 2003 (PRIMEZONE)-- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) today announced that it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI). The...